Burning second lung tumor may spare healthy lung tissue
NCT ID NCT07819669
First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time
Summary
Researchers are testing a lung-sparing approach for people who have two or more primary lung cancers in the same lung at the same time. In one group, surgeons remove the main tumor through small incisions and use a heat probe guided by CT scans to destroy the second tumor during the same operation. In the other group, surgeons remove both tumors through small incisions. The trial measures how much lung function participants keep six months after surgery, along with cancer recurrence, complications, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- radiofrequency ablation, a procedure that uses heat to destroy tumor tissue
- What this could lead to
- If the combined approach works, people with more than one lung cancer in the same lung could keep more breathing capacity after treatment.
- What could go wrong
- The trial is still testing whether burning the second tumor controls cancer as well as removing it. Ablation can leave cancer behind or damage nearby tissue, and the results may not apply to tumors in other locations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 to 80 years, inclusive. * Diagnosis of synchronous ipsilateral multiple primary lung cancer based on imaging and/or biopsy findings and confirmed by a multidisciplinary team. * The main lesion is considered suitable for video-assisted thoracoscopic lobectomy or sublobar resection, with complete resection anticipated. * The secondary lesion is considered suitable for both video-assisted thoracoscopic sublobar resection and intraoperative CT-guided radiofrequency ablation. * Eastern Cooperative Oncology Group performance status of 0 or 1. * Preoperative forced expiratory volume in 1 second of at least 50% of the predicted value. * Ability to understand the study requirements and willingness to provide written informed consent. Exclusion Criteria: * Distant metastatic disease or N2 or N3 lymph node involvement. * Severe cardiac or pulmonary dysfunction that would preclude the planned surgery, anesthesia, or radiofrequency ablation. * Previous pulmonary surgery. * Pregnancy or breastfeeding. * Active bleeding disorder or severe coagulation abnormality. * Uncontrolled pulmonary infection or active pulmonary tuberculosis. * The secondary lesion cannot be safely accessed using the intraoperative CT-guided radiofrequency ablation system. * The secondary lesion is adjacent to a major blood vessel or another critical structure such that radiofrequency ablation is considered unsafe or unsuitable.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple primary lung cancers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Shenzhen, 518116, China
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
Beijing, 100021, China
-
Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University
Taiyuan, Shanxi, 030013, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.